<DOC>
	<DOCNO>NCT02383368</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability ASP4132 determine maximum tolerate dose recommended phase 2 dose ASP4132 . The study also determine pharmacokinetics ( PK ) ASP4132 evaluate preliminary antitumor activity .</brief_summary>
	<brief_title>A Dose Escalation Expansion Study ASP4132 Subjects With Advanced Refractory Tumors Lymphoma</brief_title>
	<detailed_description>The study consist two part conduct sequentially : Part 1 ( dose escalation ) Part 2 ( dose expansion ) . Subjects participate Part 1 Part 2 .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Subject life expectancy 3 month Subject agree participate another interventional study treatment . Subject Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 . Female subject must either : 1 . Of nonchild bear potential : postmenopausal ( define least 1 year without menses ) prior Screening , , document surgically sterile status post hysterectomy 2 . Or , childbearing potential , agree try become pregnant study 90 day final study drug administration ; heterosexually active must use two form birth control Male subject female spouse/partners childbearing potential must use highly effective contraception consist two form birth control ( one must barrier method ) start Screening continue throughout study period 90 day final study drug administration . Subject must advance and/or metastatic , histologically cytologically documented cancer lymphoma , available standard therapy show provide clinical benefit . Subject absolute neutrophil count &lt; 1000/μL , platelet count &lt; 75,000/μL , hemoglobin &lt; 8 g/dL ( &lt; 5 mmol/L ) Screening Subject total serum bilirubin ≥1.5 time upper limit normal ( ULN ) , serum alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) &gt; 3 time ULN , albumin ≤ 3.0 g/dL Screening . Subject abnormality serum sodium , potassium , chloride , calcium magnesium level ≥ Grade 2 screening ( CTCAE Version 4.03 ) . Subject know elevation serum lactate screen ˃ 2x institutional ULN Subject estimate glomerular filtration rate ( eGFr ) &lt; 60ml/min calculated modification diet Renal disease ( MDRD ) Equation . Subject QTcF &gt; 450 msec male subject &gt; 470 msec female subject screen 12 lead ECG . Subject Neuropathy ≥ Grade 2 Screening . Subject Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus currently treat insulin sulfonylurea . Subject concomitant active second malignancy unless remission achieve least 3 year prior study entry subject long therapy malignancy . Subject significant cardiovascular disease Subject know history acute chronic hepatitis B ( HBV ) , HIV hepatitis C ( HCV ) infection . Subject serious/active bacterial , viral fungal infection require systemic treatment . Subject significant gastrointestinal abnormality , include ulcerative colitis , chronic diarrhea associate intestinal malabsorption , Crohn 's disease , and/or prior surgical procedure affect absorption requirement intravenous ( IV ) alimentation . Subject active central nervous system ( CNS ) metastases control prior surgery radiotherapy ( subject must steroids ) . Subjects sign symptom suggestive brain metastasis eligible unless brain metastasis rule brain MRI/CT . Subject concurrent severe uncontrolled medical disease organ system dysfunction , opinion Investigators , would limit life expectancy &lt; 3 month . Subject psychiatric disorder alter mental status would preclude understand informed consent process and/or completion necessary study procedure . Subject difficulty swallow large pill . Subject currently treat biguanides agent know increase risk lactic acidosis . Subject unavoidable concomitant treatment drug know cause Torsades de Pointes . Subject radiotherapy surgery within 4 week prior treatment ASP4132 . Subject discontinue previous systemic therapy cancer include chemotherapy , immunotherapy , biological therapy least 14 day prior initiation ASP4132 . Subject fully recover acute toxicity ( except alopecia ) prior anticancer therapy . Subject require concomitant use strong CYP3A4 inhibitor inducer .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>ASP4132</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Refractory Solid Tumors</keyword>
</DOC>